Peptides derived from Plasmodium falciparum leucine-rich repeat 1 bind to serine/threonine phosphatase type 1 and inhibit parasite growth in vitro. by Pierrot, Christine et al.
LSHTM Research Online
Pierrot, Christine; Zhang, Xiguang; Zhangi, Gigliola; Freville, Aline; Rebollo, Angelita;
Khalife, Jamal; (2018) Peptides derived from Plasmodium falciparum leucine-rich repeat 1
bind to serine/threonine phosphatase type 1 and inhibit parasite growth in vitro. DRUG
DESIGN DEVELOPMENT AND THERAPY, 12. pp. 85-88. ISSN 1177-8881 DOI:
https://doi.org/10.2147/DDDT.S153095
Downloaded from: http://researchonline.lshtm.ac.uk/4653832/
DOI: https://doi.org/10.2147/DDDT.S153095
Usage Guidelines:
Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
https://researchonline.lshtm.ac.uk
© 2018 Pierrot et al. This work is published by Dove Medical Press Limited, and licensed under a Creative Commons Attribution License.  
The full terms of the License are available at http://creativecommons.org/licenses/by/4.0/. The license permits unrestricted use, distribution, 
and reproduction in any medium, provided the original author and source are credited.
Drug Design, Development and Therapy 2018:12 85–88
Drug Design, Development and Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
85
R e s e a R c h  L e T T e R
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/DDDT.S153095
Peptides derived from Plasmodium falciparum 
leucine-rich repeat 1 bind to serine/threonine 
phosphatase type 1 and inhibit parasite growth 
in vitro
christine Pierrot1
Xiguang Zhang2
Gigliola Zhangi2
aline Fréville1
angelita Rebollo2
Jamal Khalife1
1center for Infection and Immunity 
of Lille, U1019 – UMR 8204, Institut 
Pasteur de Lille, Université de Lille, 
Lille cedex, 2cIMI Paris, UPMc/
Inserm U1135, Paris, France
Introduction
The biogenesis of protein phosphatase 1 (PP1) holoenzyme in eukaryotes requires 
diverse regulatory subunit proteins (RSPs) that bind to the highly conserved PP1 
catalytic subunit (PP1c) and direct its spatiotemporal activity as well as its specificity. 
Several studies demonstrated that most RSPs share a canonical common binding motif, 
the RVXF motif, which is present in ~85% of RSPs and is considered as the main con-
tributor for the interaction to PP1c.1 In Plasmodium falciparum (Pf), our earlier studies 
revealed that leucine-rich repeat 1 (LRR1), one of the major RSPs of PfPP1 and an 
ortholog of human and yeast Sds22, lacks the RVXF motif. The amino acids sequence 
of PfLRR1 exhibits nine leucine-rich repeats (LRRs) and a hydrophobic region at the 
C-terminal end, known as the LRR cap motif.2 In this work, we identified the PP1-
binding peptides of PfLRR1 and examined their capacity to affect Pf growth.
Methods
Peptides
Peptides were synthesized in an automated multiple peptide synthesizer with solid-
phase procedure and standard fluorenylmethyloxycarbonyl chemistry. The purity and 
composition of the peptides were confirmed by reverse-phase high performance liquid 
chromatography and by amino acid analysis.
PP1-binding assays on cellulose-bound peptides containing 
LRR1 sequence
Overlapping dodecapeptides scanning the whole LRR1 sequence were prepared by 
automated spot synthesis (Abimed, Langerfeld, Germany) onto an amino-derived 
cellulose membrane, as described.3,4 The membrane was developed as described by 
Tian et al.5
Binding of PfPP1 with synthetic-derived peptides 
from PfLRR1 using an enzyme-linked immunosorbent 
based-assay
The method has been described previously in detail and was used without any 
modification.6,7
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Parasite culture and growth inhibition 
assay of blood-stage parasites
These methods have been extensively described.6
Pf sporozoites
Pf (NF54) sporozoites were isolated by aseptic dissection of 
the salivary glands of infected Anopheles stephensi obtained 
from the Department of Medical Microbiology, University 
Medical Centre, St Radboud, Nijmegen, the Netherlands.
Primary hepatocyte in vitro cultures
Human primary hepatocytes were isolated from liver seg-
ments obtained from adult patients undergoing partial 
hepatectomy as described by Dembélé et al.8
Infection and drug assays
The protocol has been described by Barata et al.9
Parasite quantification
Pre-erythrocytic parasites were detected by immunofluores-
cence following the protocol described by Dembélé et al.8
Results and discussion
To better define the PP1-binding sites of PfLRR1, we 
performed a peptide array screening with overlapping 
dodecapeptides, including the LRR cap. Dot blot analysis 
presented in Figure 1A revealed that two sites were able to 
bind to PP1. The first PP1c-binding sequence of PfLRR1, 
IENLQNCKKLRLLELGYNKIRM, contains an LRR motif, 
and the second sequence, ENYRKTIIHILPQLKQLDAL, 
corresponds to the LRR cap of the protein. The specificity 
of this binding was confirmed by the absence of binding of 
an irrelevant protein (Figure 1A).
Based on these results, the ability of the two binding 
peptides to inhibit Pf growth was then examined. To this 
end, we synthesized peptides containing the shuttle sequence 
VKKKKIKAEIKI (Mut3-DPT-Sh1), known to deliver pep-
tides to cells,10 and the binding sequence 1 (Mut3-LRR1.1) 
or 2 (Mut3-LRR1.2) (Figure 1B). To evaluate whether 
these chimeric cell-penetrating and cell-interfering pep-
tides retained their capacity to bind to PP1, their binding to 
recombinant PfPP1 was first explored. Results presented in 
Figure 1C confirmed that PfPP1 was able to bind to Mut3-
LRR1.1 and Mut3-LRR1.2. These results differ from those of 
human Sds22 structure-binding studies. Indeed, single-point 
mutations in LRRs of human Sds22 and synthetic peptides 
showed that the PP1-binding regions extended over the 
last six LRRs.11,12 In the case of PfLRR1, our data showed 
for the first time that, besides the engagement of one LRR 
motif, the LRR cap seems to contribute to the interaction of 
PfLRR1 with PP1.
Next, we examined the effect of these chimeric peptides 
on the growth of Pf in vitro. As shown in Figure 2A, the 
peptide Mut3-LRR1.2 inhibited around ~80% the growth 
of Pf blood-stage parasites at the highest concentration. The 
peptide Mut3-LRR1.1 exhibited an inhibition of ~50%. The 
control Mut3-DPT-Sh1 showed only an inhibition of ~10% 
at any concentration used.
The antiparasitic activity of the two chimeric peptides 
was also tested on the in vitro hepatic stage of Pf. Figure 2B 
Figure 1 (A) Mapping of PfLRR1–PP1 interaction. Overlapping dodecapeptides with 
two amino acids shift covering PfLRR1 sequence were bound to a solid support. 
The membrane was incubated sequentially with PP1 protein and anti-PP1 antibody, 
followed by a secondary antibody. The membrane was revealed using the ecL 
system. as a control, the membrane was also hybridized with the irrelevant protein 
Ras. (B) sequences of chimeric penetrating peptides (penetrating sequence is 
bolded). (C) Binding of chimeric peptides to PfPP1 analyzed in an eLIsa-based assay. 
Peptides were coated in 96-well plates and incubated with biotinylated recombinant 
PfPP1. Results are from one representative experiment out of two (mean ± standard 
deviation). LRR1.1 indicates site 1; LRR1.2 indicates site 2.
Abbreviations: Pf, Plasmodium falciparum; LRR1, leucine-rich repeat 1; PP1, protein 
phosphatase 1; PfPP1-biot, biotinylated PfPP1; ecL, enhanced chemiluminescence; 
eLIsa, enzyme-linked immunosorbent assay.
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shows that both peptides have a significant inhibitory activity 
on Pf liver-stage development, but that the Mut3-LRR1.2 
peptide is more active, as in the case for the blood stage. 
These data could be explained by the capacity of binding 
motifs to disrupt/destabilize PfLRR1–PfPP1 interaction in 
Pf, leading to parasite growth inhibition.
The evaluation of the toxicity of both peptides analyzed 
on primary human hepatocytes at different concentra-
tions that were active on parasites showed that they did 
not affect the host cell viability (data not shown). Taken 
together, these results confirm that these two peptides have 
specific antiplasmodial activity on both Pf erythrocytic and 
hepatic stages. In addition, these observations support our 
previous data showing the antiplasmodial capacity of RVXF-
derived peptides6 and raise the possibility for the synthesis 
of stable, administrable peptides affording high selectivity/
potency and/or small molecules specifically targeting Pf 
RSPs of PP1c.
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Figure 2 In vitro effect of PfLRR1-derived peptides on Pf growth. (A) In vitro effect of chimeric peptides on the erythrocytic stages of Pf. Peptides at different 
concentrations were incubated with Pf3D7-infected erythrocytes for 48 h. Two control peptides were used: Mut3-DPT-sh1 (VKKKKIKaeIKI) and an unrelated peptide from 
PF3D7_1010600 gene (VKKKKIKREIKIFGEKKKFGEKKK). Parasitemia was measured by flow cytometry analysis after SYBR Green I staining. Controls for the calculation of 
% of inhibition were obtained with 500 nM chloroquine (100% of inhibition) or medium (0% of inhibition). Results of one representative experiment out of three are shown 
as mean ± standard deviation. (B) In vitro effect of chimeric peptides on hepatic stages of Pf. sporozoites were obtained from infected salivary glands of Anopheles stephensi. 
human hepatocytes were isolated from liver segments obtained from adult patients undergoing partial hepatectomy. Different concentrations of peptides were added to the 
culture medium 3 h after infection of hepatocytes with Pf sporozoites and renewed every day for 5 days. Following fixation, the culture plates were then stained with anti-Pf 
hsp70 polyclonal antibody followed by a fluorochrome-labeled secondary antibody. Parasites were detected under fluorescence microscope. Results of one representative 
experiment out of two are shown as mean ± standard deviation. LRR1.1 indicates site 1; LRR1.2 indicates site 2.
Abbreviations: Pf, Plasmodium falciparum; LRR1, leucine-rich repeat 1.
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